Abstract
Cancer-associated malnutrition and cachexia are common, clinically serious syndromes characterized not only by weight loss but also by functional decline, inflammatory activation, and metabolic derangements including insulin resistance and altered carbohydrate handling[1, 2]. In routine practice, patients at nutritional risk are frequently supported with standard oral nutritional supplements (ONS) and commercial enteral formulas that deliver a large fraction of calories as rapidly digestible carbohydrates, often via maltodextrin, glucose-containing carbohydrate blends, and/or added sugars, as reflected both in ingredient descriptions and in macronutrient energy distributions on product labels and formula surveys[3–5]. This creates a clinical paradox: metabolic states associated with worse cancer outcomes—hyperglycemia and hyperinsulinemia—are mechanistically linked to tumor-promoting signaling through insulin/IGF-1 pathways and glycolytic (Warburg-like) tumor metabolism, while observational evidence across cancer populations links higher glucose exposure to shorter survival and poorer outcomes[2, 6–10]. Meanwhile, cachexia itself is driven by inflammation and insulin resistance, implying that high-glycemic nutritional support could theoretically exacerbate the metabolic context that accompanies muscle wasting and functional decline[1, 2].
This review synthesizes evidence available in the provided dataset on (i) carbohydrate dominance in standard formula composition, (ii) mechanistic and clinical links between hyperglycemia/insulin signaling and cancer progression, and (iii) emerging low-glycemic and anti-inflammatory alternatives spanning modified enteral macronutrient profiles, fiber-containing formulas, and whole-diet interventions associated with improved inflammatory or survival signals[3, 11–17]. The evidence base is strongest for associations between hyperglycemia and prognosis in specific cancers and for mechanistic plausibility, while direct randomized survival trials comparing high- versus low-glycemic medical foods in oncology remain limited within the present source set[6–8]. A practical path forward is to treat “caloric adequacy” and “metabolic compatibility” as simultaneous clinical goals and to prioritize rigorously designed trials of lower-glycemic, higher-fat (including monounsaturated fat) and fiber-containing formulations in metabolically vulnerable oncology patients[11, 12].
Introduction
Cancer cachexia is a clinically defined syndrome requiring >5% weight loss in <12 months plus at least three of five features: decreased muscle strength, fatigue, anorexia, low fat-free mass index, and abnormal biochemistry including increased C-reactive protein (CRP), anemia, and low serum albumin[1]. The syndrome is common—reported to occur in up to 80% of patients—and is implicated in approximately 20% of cancer-related deaths[1]. Importantly, cachexia cannot be reduced to “too few calories,” because reduced intake alone does not explain cachexia pathogenesis in about half of cancer patients, and cachexia reflects a chronic negative energy and protein balance driven by both reduced food intake and metabolic change[2].
Within this clinical reality, standard oral nutritional supplements (ONS) and commercial enteral formulas are widely used as pragmatic tools to add energy and protein when patients cannot meet needs through ordinary foods or require tube feeding[1, 3]. The problem addressed here is not nutritional support per se, but rather the metabolic profile of the calories being delivered. In formula surveys and ingredient descriptions, carbohydrates are often described as the largest energy source in enteral products and are commonly delivered via maltodextrin and other glucose polymers, sometimes combined with corn syrup and other rapidly available carbohydrate sources[3, 18]. Label examples for oncology-oriented ONS similarly show carbohydrate energy shares around ~45–47% of total energy, with substantial “total sugars” content reported per serving or per 100 mL[4, 5].
This creates a plausible mismatch between the metabolic context of many oncology patients—where insulin resistance, inflammatory activation, and hyperglycemia can be present—and a feeding strategy that emphasizes rapidly absorbed carbohydrate delivery[1, 6]. Because hyperglycemia and hyperinsulinemia are linked in both mechanistic frameworks and clinical cohorts to tumor-favoring biology and worse outcomes, carbohydrate-dominant formulas raise a legitimate medical concern that caloric replacement may be inadvertently metabolically pro-oncogenic in some settings, even when it improves short-term energy delivery[2, 6–8].
The composition problem
Standard medical-nutrition products used in oncology and in tube feeding can contain carbohydrate as a dominant or major macronutrient contributor, often in forms expected to produce rapid glucose availability. A European descriptive analysis of enteral formulas states that carbohydrates “represent the largest energy source in enteral formulae,” and that carbohydrate sources include maltodextrin plus varying amounts of corn syrup and other mono-/oligosaccharides and polyols, including fructose, inulin, and maltitol[3]. A related statement in the same analysis notes that “the major energy source is provided by carbohydrates in the form of polysaccharides and glucose,” while lipid content comes mainly from long-chain triglycerides (LCT) and/or mixtures including medium-chain triglycerides (MCT)[3]. Educational material on nutrition support similarly lists commonly used carbohydrate sources as corn syrup solids, hydrolyzed cornstarch, maltodextrins, and other glucose polymers, and notes that simple sugars (sucrose and glucose) enhance palatability of oral supplements but increase osmolality[18].
ONS labels in the provided dataset offer concrete quantitative examples. One oncology-oriented ONS reports, per 100 mL, 19.1 g carbohydrate corresponding to 47% of energy, alongside a “Sugars” value of 13.6 g[4]. Another oral nutrition product reports carbohydrate providing 45% of total energy intake (TEI), with total sugars quantified (17.0 g per 100 g powder; 12.6 g per serving) and sucrose included among ingredients[5]. These data do not establish a universal carbohydrate fraction for all ONS and enteral formulas, but they document that commercially available medical foods can be carbohydrate-heavy and contain substantial sugars, which is clinically relevant given the glucose-linked mechanisms and outcomes reviewed later[4, 5].
Macronutrient distributions vary by formula category. In the European analysis, hyperproteic–normocaloric formula groups were reported to have higher protein content (20.7–22.9%) with lower carbohydrate content (43.3%), while malabsorption formulas averaged 51.9% of total energy from carbohydrates and surgery formulas averaged 50.5%[3]. Such variability implies that “carbohydrate dominance” is not inevitable, but it is common enough—and explicitly described as the largest energy source in enteral formulae—to merit scrutiny in oncology patients vulnerable to hyperglycemia and insulin resistance[3].
The table below summarizes key composition and glycemia-related quantitative examples available from the dataset, illustrating how both standard labels and modified formulas can differ.
Why this is a medical problem
The clinical stakes are elevated because cachexia and cancer-associated malnutrition occur in physiologic contexts where carbohydrate handling is disrupted, inflammation is increased, and tumor biology may be sensitive to the glucose–insulin milieu[1, 6]. Within the source set, multiple lines of evidence support concern:
- tumor metabolic reprogramming toward glycolysis and increased glucose uptake,
- insulin/IGF-1 signaling pathways that favor proliferation and growth, and
- observational clinical evidence that higher glucose exposure is associated with worse survival in several cancer settings[2, 6–9].
Warburg biology
One mechanistic synthesis describes the Warburg effect as a shift in cancer cells toward an “inefficient glycolytic mode” that directs a major nutrient flux into glycolysis rather than oxidative phosphorylation to meet excess energy demands, a metabolic reprogramming widely regarded as a hallmark of cancer metabolism[8]. The same synthesis notes that cancer cells uptake more glucose than normal cells, a phenomenon detectable by positron emission tomography (PET), and that this may provide a selective advantage in a nutrient-limiting environment[8]. Within this framework, hyperglycemia is positioned as a condition that removes nutrient restrictions by making glucose “abundantly available,” and thus “promotes glycolysis in various cancer cells,” including through increased expression of glycolytic enzymes such as hexokinase-II and pyruvate kinase M[8].
Additional mechanistic framing suggests that hyperglycemia may increase cancer risk and promote cancer growth even independent of insulin, “mainly due to cancer dependence on aerobic glycolysis” (Warburg-type ATP generation)[19]. Preclinical observations cited in glioblastoma literature further support a substrate-availability concept: whereas healthy mice show only minimal brain glucose increases after intraperitoneal glucose, mice with gliomas were reported to experience a 2.5-fold increase in intratumoral glucose after induction of hyperglycemia, and high glucose within glioblastoma could provide extra substrate for glycolytic metabolism and support unchecked tumor growth[7].
At the same time, tumor metabolism is flexible. A mechanistic review states that fructose can serve as an alternative carbon source used by tumor cells to maintain metabolism; fructose metabolites can enter glycolysis and bypass phosphofructokinase, potentially facilitating tumorigenesis and development[20]. This plasticity implies that simply reducing glucose exposure may not deprive tumors of all usable carbon sources, but it does not negate evidence that hyperglycemia and high glucose availability can favor glycolysis and tumor-associated pathways[8, 20].
Insulin and IGF signaling
Carbohydrate-rich meals are linked in one oncology nutrition protocol to elevations in insulin and IGF-1: high insulin and IGF-1 levels resulting from chronic ingestion of carbohydrate-rich Western diet meals are described as directly promoting tumor cell proliferation via the insulin/IGF-1 signaling pathway[2]. In clinical and mechanistic discussions of breast cancer, hyperglycemia is proposed to influence progression and outcomes through pathways mediated by high insulin/IGF levels, sex hormones, and inflammatory markers, and hyperinsulinemia is explicitly described as augmenting cell proliferation and survival[6].
Insulin itself is framed as a mitogenic growth factor. In glioblastoma-related synthesis, insulin is described as a member of a growth factor family that, similar to IGF-1/2, may promote tumor proliferation; in vivo studies are cited as showing that high insulin levels enhance colorectal and breast cancer cell proliferation via receptors on tumors[7]. A diabetes-related cancer meta-analytic synthesis further proposes that elevated circulating insulin could promote carcinogenesis directly by stimulating insulin receptor signaling and indirectly by suppressing IGF-binding proteins 1 and 3, increasing IGF-1 bioavailability for its receptors[21].
At the pathway level, insulin/IGF ligand binding recruits insulin receptor substrates (IRS 1–4) and activates PI3K and MAPK signaling; downstream Akt activation drives mTOR signaling, protein synthesis, cell growth, and preparation for mitosis—events that favor tumor growth[9]. Insulin and IGF-I signaling also activate Akt, which phosphorylates TSC-2 and releases inhibition of mTOR, while energy stress can activate AMPK, which prevents protein production for cell growth and proliferation[9]. A further mechanistic concern is the concept of hyperglycemic “memory”: after cancer cells are exposed to hyperglycemic conditions, a subset of oncogenic pathways may remain permanently activated even after normalization, with upregulation of the Nrg1-HER3 pathway in tumors derived from hyperglycemic patients/rodents and faster growth even under euglycemic conditions[10].
Finally, the dataset includes direct evidence that modifying an ONS carbohydrate type can reduce insulin exposure acutely. In a randomized crossover evaluation of an ONS in which tapioca resistant maltodextrin replaced part of tapioca maltodextrin, the insulin peak decreased from 61.30 ± 12.14 μIU/mL (original) to 42.74 ± 10.24 μIU/mL (higher resistant maltodextrin), and insulin AUC over 180 minutes decreased from 3470.12 ± 531.86 to 2320.71 ± 570.76 μIU·min/mL, corresponding to a 33.12% reduction (p = 0.039)[22]. While this is not an oncology outcome study, it demonstrates that formulation design can meaningfully alter insulin dynamics, which is relevant given the tumor-promoting roles attributed to insulin/IGF signaling[2, 6, 7, 9].
Hyperglycemia and prognosis
Across multiple observational cohorts in the dataset, higher glucose exposure is associated with worse survival outcomes in cancer, though not uniformly across all cancers or cohorts. In advanced breast cancer patients receiving palliative chemotherapy, mean glucose >130 mg/dL during treatment was associated with poorer overall survival (27.0 vs 12.0 months; P = 0.023), and mean glucose >130 mg/dL independently predicted worse survival (HR 2.8, 95% CI 1.1–7.3; P = 0.034)[6]. In subgroup results from the same cohort, nondiabetic patients compared with diabetic patients who had hyperglycemia (average fasting glucose >130 mg/dL) had longer overall survival (36.0 vs 12.0 months; P = 0.003), and among diabetic patients, “proper metabolic control” (average fasting glucose <130 mg/dL) was associated with superior overall survival relative to hyperglycemia (overall survival not reached vs 12.0 months; P = 0.01)[6].
In newly diagnosed glioblastoma, higher time-weighted mean glucose was associated with progressively shorter median survival across quartiles (14.5 months in the lowest quartile vs 9.1 months in the highest quartile), and adjusted hazard ratios increased across quartiles, reaching 1.57 (95% CI 1.02–2.40) in the highest quartile (P = 0.041 for trend)[7]. Moreover, for every 10 mg/dL increase in time-weighted mean glucose, mortality risk increased (HR 1.05, 95% CI 1.02–1.07; P < 0.0001), with sensitivity analyses broadly consistent with this association[7]. Infection showed a trend-level association with mean glucose (OR 1.06 per 10 mg/dL; P = 0.09), yet adjusting for infection did not remove the glucose–survival association (adjusted HR 1.03 per 10 mg/dL; P = 0.035)[7].
Preclinical data in tumor-bearing mice align directionally with these clinical associations. In colon-26 tumor-bearing mice used as hyperglycemic models when glucose exceeded 300 mg/dL, survival was significantly shorter in hyperglycemic mice, and the tumor-inhibitory rate of FOLFOX chemotherapy was attenuated under hyperglycemia (e.g., 48% vs 28% at day 7; 53% vs 14% at day 21 in control vs hyperglycemic mice)[23]. Broader synthesis cited in the dataset reports a meta-analysis of eight studies totaling 4,342 patients in which hyperglycemia was associated with adverse disease-free and overall survival[8].
However, negative findings also exist. In a metastatic colorectal cancer cohort, median overall survival across mean glucose quartiles (22.6, 20.1, 18.9, 17.9 months) did not differ significantly (p = 0.643)[24]. Collectively, this pattern supports a cautious but clinically relevant interpretation: hyperglycemia is often, though not universally, associated with poorer outcomes, and the strength of association may depend on tumor type, treatment context, comorbid diabetes, and other factors not fully resolvable within the dataset[6–8, 24].
Glycemic index and glycemic load
Epidemiologic evidence relating dietary glycemic index (GI) and glycemic load (GL) to cancer risk suggests modest and site-dependent associations. In a meta-analysis, relative risks for breast cancer were close to null for both GI and GL (e.g., GL RR 1.05, 95% CI 0.97–1.13), while endometrial cancer showed borderline estimates (GL RR 1.12, 95% CI 0.97–1.30)[25]. For colorectal cancer, GI was associated with increased risk (RR 1.20, 95% CI 1.07–1.34) while GL was not significantly associated (RR 1.09, 95% CI 0.97–1.22), and pancreatic cancer showed no association for GL (RR 0.99, 95% CI 0.84–1.17) in the cited analysis[25].
A separate meta-analysis of 36 prospective cohort studies including 60,811 diabetes-related cancer cases concluded that associations between high glucose-response diets and diabetes-related cancer risks were “modest-to-weak,” with pooled RR 1.07 (95% CI 1.04–1.11) for GI and 1.02 (95% CI 0.96–1.08) for GL when comparing highest vs lowest categories[21]. Site-specific results in this analysis reported significant associations for GI with breast cancer (RR 1.06) and colorectal cancer (RR 1.08), and for GL with endometrial cancer (RR 1.21), while GL was not significantly associated with colorectal cancer (RR 0.99) and evidence of publication bias was noted (P < 0.03)[21]. These data suggest that while GI/GL may capture relevant metabolic exposures at the population level, associations with cancer incidence are generally small and vary by site, emphasizing the need to distinguish cancer prevention epidemiology from the metabolic management of patients with established cancer undergoing treatment[21].
Inflammation and metabolic stress
Inflammation is not merely a comorbidity in cancer cachexia; it is incorporated into diagnostic features (e.g., increased CRP) and is mechanistically implicated through cytokines. Cachexia is associated with increased inflammatory cytokines and is accelerated by inflammatory signaling, with TNF-α, IL-6, IL-1, and interferon-γ described as able to evoke cachexia[1]. This is clinically relevant because cachexia is also linked to insulin resistance and altered carbohydrate metabolism, implying that the inflammatory state and the glucose–insulin state are intertwined in the very patients most likely to receive high-calorie formulas[1].
Within the dataset, “dietary inflammation” constructs—capturing the overall inflammatory potential of diet patterns—are linked to outcomes after cancer diagnosis. In stage III colon cancer, a very pro-inflammatory diet pattern (high EDIP score) was associated with an 87% higher risk of death compared with a very anti-inflammatory pattern, while disease-free survival did not significantly differ[15]. In a post-diagnosis dietary inflammatory index analysis, women consuming a more pro-inflammatory diet after cancer diagnosis had higher all-cause mortality (HR Q4:Q1 = 1.18; P trend = 0.015), and when diet plus supplements were included, a pro-inflammatory score was associated with substantially higher all-cause mortality (HR Q4:Q1 = 1.63; P trend < 0.0001)[16]. These observational signals do not isolate “sugar” as the causal exposure, but they support the clinical premise that diet quality—specifically its inflammatory profile—matters for outcomes beyond calorie count alone[15, 16].
A narrower mechanistic bridge between high sugar exposure and inflammation appears in a preclinical example: a water extract of Lycium ruthenicum Murray ameliorated neuroinflammation and cognitive deficits induced by a high-fructose diet, implicating a gut–liver–brain axis mechanism in diet-induced inflammation models[20]. While not oncology-specific, it illustrates that high-fructose dietary patterns can induce inflammatory phenotypes that are modifiable by dietary bioactives in experimental systems, which is relevant to anti-inflammatory diet design concepts in cancer supportive care[20].
Iatrogenic dysglycemia in enteral feeding
The dataset provides direct evidence that enteral formula macronutrient distribution affects glycemic responses. In dexamethasone-induced hyperglycemic rats, an enteral solution containing 50% fat and 26% carbohydrate reduced the post-administration blood glucose increase compared with a formulation containing 20% fat and 64% carbohydrate[12]. In non-diabetic patients receiving jejunal feeding via jejunostomy, a carbohydrate-restricted/high monounsaturated fat formula reduced reactive hypoglycemia burden (AUC <70 mg/dL: 0.63 vs 16.7 mg·h/dL) and increased the minimum glucose level (78.4 vs 61.8 mg/dL) relative to control[11].
Although reactive hypoglycemia is not identical to hyperglycemia, these findings demonstrate a core point with direct clinical relevance: enteral macronutrient engineering can materially change glycemic dynamics, and higher-carbohydrate feeding can plausibly worsen dysglycemia in metabolically stressed settings[11, 12]. Given observational evidence that higher mean glucose exposure during cancer treatment is associated with worse survival in multiple cohorts, the glycemic consequences of formula composition become a medical issue rather than a purely nutritional or logistical one[6, 7].
The cachexia paradox
Cachexia is often treated clinically as a caloric deficit state, but the source set emphasizes that its pathogenesis involves metabolic and inflammatory components. Major carbohydrate metabolism alterations in cachexia include increased gluconeogenesis using amino acids and lactic acid along with insulin resistance, and increased gluconeogenesis together with peripheral insulin resistance decreases glucose use in muscle and contributes to muscle wasting[1]. Cachexia is accelerated by inflammatory cytokines, and specific cytokines (TNF-α, IL-6, IL-1, interferon-γ) are described as evoking cachexia[1]. Thus, the metabolic state of cachexia includes both impaired glucose utilization in muscle and inflammatory activation[1].
This creates a paradox for high-glycemic nutritional support. If a cachectic patient has insulin resistance and decreased muscular glucose use, then delivering large carbohydrate loads may preferentially drive hyperglycemia and hyperinsulinemia rather than effective anabolic substrate use by skeletal muscle, while also intersecting with tumor-favoring glucose/insulin pathways described earlier[1, 2, 6, 8]. The dataset does not contain direct trials showing that carbohydrate-heavy ONS worsen cachexia outcomes, so this remains a mechanistically grounded concern rather than a proven causal claim[1, 2, 8]. Nonetheless, the logic is clinically coherent given that cachexia is not explained by energy deficit alone in about half of patients and is accompanied by metabolic change and insulin resistance[1, 2].
Intervention evidence in cachexia and malnutrition also suggests that nutritional support benefits are not universal across endpoints. In a systematic review of 28 studies, indices of inflammation and immune function (especially infections, complications, plasma CRP, and serum cytokine levels) improved in 65% of selected studies, whereas nutritional status indices, quality of life, and hospital stay duration improved in about 40% of studies[1]. In a 12-week randomized trial comparing two hypercaloric, hyperproteic oral supplements in cancer patients with weight loss, biochemical changes across all patients were limited: prealbumin increased (p < 0.05) and CRP decreased (p < 0.05), with HDL tending to increase (p = 0.06)[26]. These data support the idea that nutritional interventions can partially attenuate inflammation markers in some contexts, but they also underscore that the “right calories” question remains open—particularly for metabolically compromised patients in whom glucose exposure may matter for both host and tumor biology[1, 6, 26].
Evidence on anti-inflammatory and low-glycemic alternatives
The dataset contains several classes of “alternatives,” ranging from macronutrient-modified enteral formulas and carbohydrate-type modifications to whole-diet interventions and diet-pattern evidence linking anti-inflammatory diets to improved survival signals. However, the strength of evidence differs by intervention type: glycemia effects of macronutrient modification are demonstrated directly, while definitive oncologic endpoints (tumor response, progression-free survival, overall survival) for specific low-glycemic medical foods are not directly established in the provided sources[6, 8, 11, 12].
Low-carbohydrate and glycemia-targeted formula designs
A practical, evidence-supported alternative approach within the dataset is macronutrient rebalancing toward higher fat and lower carbohydrate to blunt dysglycemia. In hyperglycemic rats, a 50% fat/26% carbohydrate enteral solution lowered the post-administration glucose rise compared with a 20% fat/64% carbohydrate formulation[12]. In non-diabetic jejunal-fed patients, a carbohydrate-restricted/high monounsaturated fat formula reduced reactive hypoglycemia AUC and increased minimum glucose compared with control feeding[11]. Together these demonstrate that dysglycemia is, at least partly, a modifiable iatrogenic variable through formula design[11, 12].
A second design lever is carbohydrate quality rather than total carbohydrate quantity. In the resistant maltodextrin substitution study, the carbohydrate macro ratio across formulas was held constant (carbohydrate:protein:fat 52:16:32), but carbohydrate source shifted from tapioca maltodextrin plus sucrose toward increasing resistant maltodextrin proportion, and this change reduced insulin peaks and AUC substantially (e.g., 33.12% reduction in insulin AUC for the higher substitution formula)[22]. This indicates that even without reducing total carbohydrate grams, shifting toward more slowly digestible/functional carbohydrate types can reduce insulin exposure, which is relevant given the tumor-promoting roles attributed to insulin/IGF signaling[6, 7, 9, 22].
An oncology-specific protocol also explicitly motivates a “high-energy–low-carbohydrate” ONS design tailored to malnourished cancer patients, described as rich in immunonutrient components and hypothesized to improve adherence and effectiveness versus a more general ONS recommendation for disease-related malnutrition[2]. While outcome data are not provided in the excerpt, the existence of this protocol supports the clinical plausibility and feasibility of deliberately lowering carbohydrate content in oncology-focused formulas as a design principle warranting clinical testing[2].
Anti-inflammatory dietary patterns
Diet-pattern evidence in the dataset supports the clinical relevance of anti-inflammatory eating patterns after cancer diagnosis. In stage III colon cancer, diets characterized as very pro-inflammatory were associated with an 87% higher risk of death compared with very anti-inflammatory diets, although disease-free survival was not significantly different[15]. Post-diagnosis dietary inflammatory index analyses similarly report increased all-cause mortality with more pro-inflammatory dietary patterns, including an HR of 1.18 (Q4:Q1) for food-only scoring and 1.63 when incorporating diet plus supplements[16].
The dataset also includes a randomized trial of a whole-food, plant-based diet in women with metastatic breast cancer (stage 4), showing biomarker shifts consistent with reduced inflammation and tumor-associated signaling. Participants were randomized to whole-food, plant-based dietary intervention (n = 20) versus usual care (n = 10) for 8 weeks; TNF-α decreased significantly by week 8 (P < .05), leptin decreased at weeks 4 and 8 (P < .001), and tumor-related markers CA15-3 and VEGF-C decreased by week 8 (both P < .05), with authors concluding the diet was associated with reductions in inflammatory and tumor markers suggesting potential to reduce inflammation and slow disease progression[14]. While this trial is short and biomarker-focused, it demonstrates that dietary pattern interventions can be feasible and can measurably change inflammatory markers relevant to cancer biology[14].
Longer-horizon survivor evidence is represented by a prospective cohort summary reporting that higher adherence to a planetary health diet was associated with reduced all-cause and cancer-specific mortality in cancer survivors and correlated with lower systemic inflammation, with mechanistic framing that inflammation may facilitate conditions for malignant cell proliferation and angiogenesis[17]. Together, these observational and trial-based pieces support a shift in oncology nutrition thinking from “calories alone” to “dietary inflammatory potential and metabolic context,” even as causal inference remains limited for many endpoints[14–16].
Omega-3 fatty acids and polyphenols
Within the ONS and enteral formula literature summarized in the dataset, omega-3 fatty acids (notably EPA and DHA) appear frequently as added functional ingredients. In a systematic review of 28 studies, 19 studies (68%) used ONS containing n-3 fatty acids or fish oil, and 9 studies indicated suppression of inflammatory responses[1]. A clinical trial protocol states mechanistically that EPA can reduce inflammation and has the potential to modulate nutritional status/body composition, and that a diet rich in omega-3 fatty acids would negatively modulate the inflammatory cascade[2]. A descriptive formula analysis reports that EPA+DHA content was present in 46% of standard formulas (n = 29) and that 45.5% of specialized diet formulas had added EPA and DHA; notably, all cancer and surgery formulations in that analysis had EPA and DHA added, whereas none for renal or pulmonary disease did[3]. A specific oncology ONS label example reports EPA and DHA amounts per 100 mL (EPA 601 mg; DHA 298 mg), illustrating the feasibility of delivering clinically meaningful omega-3 doses through medical foods[4].
For polyphenols, the dataset provides mostly mechanistic statements rather than quantitative clinical oncology outcomes. A mechanistic review notes that resveratrol is described as a calorie restriction mimic that inhibits cell proliferation and tumor angiogenesis by increasing immunosurveillance mechanisms and can function as an immunomodulator and chemosensitizing agent improving IL-2 based immunotherapy in melanoma and neuroblastoma, but no quantitative effect sizes are provided in the excerpt[8]. Given this limitation, polyphenols can be discussed as biologically plausible adjuncts, but the present dataset does not support clinical endpoint claims in oncology patients receiving polyphenol-enriched medical nutrition[8].
Blueprint for a metabolically compatible oncology medical food
A scientifically defensible blueprint, constrained to what is directly supported in the dataset, emphasizes four design pillars: (i) lowering glycemic impact by reducing carbohydrate percentage and/or changing carbohydrate type, (ii) increasing fat-derived energy—particularly monounsaturated fat in at least some contexts, (iii) incorporating fiber sources that may slow absorption and modulate glycemic response, and (iv) considering omega-3 inclusion as a common anti-inflammatory functional component used in oncology-related formulations.
First, lowering carbohydrate content and increasing fat content can blunt glycemic excursions in hyperglycemic models, as shown by lower post-administration glucose rises with 50% fat/26% carbohydrate versus 20% fat/64% carbohydrate in dexamethasone-induced hyperglycemic rats[12]. Human jejunal feeding evidence similarly supports that carbohydrate restriction with high monounsaturated fat can improve glycemic stability, reducing reactive hypoglycemia burden and increasing minimum glucose values compared with control feeding[11]. Second, shifting carbohydrate type toward resistant maltodextrin can reduce insulin peaks and total insulin exposure without changing the macronutrient ratio (52:16:32), indicating that carbohydrate quality is a feasible target for metabolic tuning[22].
Third, enteral formula surveys show that carbohydrate sources frequently include maltodextrin and corn syrup alongside prebiotic-type carbohydrates such as fructo-oligosaccharides and inulin, and that 46% of device-specific formulas contained soluble fibers from non-starch polysaccharides (including inulin, guar gum, oats, and FOS), with insoluble fiber from resistant starch and lignin[3]. While this does not establish clinical benefit in oncology outcomes, it shows that fiber inclusion is common and technically feasible in formula design and provides a rational lever for glycemic and gut-related modulation within formula constraints[3].
Fourth, omega-3 inclusion is widely used in oncology-related formulas and trials: 68% of ONS in a 28-study review contained n-3 fatty acids or fish oil, and oncology/surgery formulations in a European analysis all contained EPA/DHA, supporting omega-3 as a practical anti-inflammatory design choice in oncology medical nutrition[1, 3]. Mechanistic rationale is explicitly provided in the protocol statements that EPA can reduce inflammation and that omega-3 rich diets negatively modulate inflammatory cascades[2].
Because the dataset does not provide direct comparative oncology outcomes for “low-glycemic” versus “standard high-glycemic” medical foods, the blueprint should be interpreted as a rational, evidence-informed design hypothesis rather than a proven standard of care[2, 11, 12]. The most defensible recommendation is to treat these composition choices as candidate interventions to be tested, rather than as established therapy, particularly in patients with documented hyperglycemia or insulin resistance where observational evidence links glucose exposure to worse outcomes[6–8].
Why the status quo persists
Within the provided evidence set, direct analyses of economic incentives, manufacturing costs, or regulatory inertia are not available, so any strong claims about “why” carbohydrate-heavy formulas dominate cannot be made from these sources alone[3, 18]. Nevertheless, the dataset does document several practical drivers that plausibly shape formulation choices.
First, carbohydrates are explicitly described as the largest energy source in enteral formulas and as the “major energy source” in the form of polysaccharides and glucose in formula descriptions, reflecting a common formulation architecture rather than an exceptional niche product design[3]. Second, educational material notes that simple sugars (sucrose and glucose) enhance the palatability of oral supplements, a practical consideration in patients with poor appetite and taste changes, even though it increases osmolality[18]. Third, the wide use of maltodextrins and other glucose polymers in nutrition support carbohydrate sourcing is described as common practice, reinforcing that rapid-carbohydrate ingredients are embedded in standard formulation toolkits[18].
Finally, the clinical imperative to deliver calories and protein quickly in cachectic patients is substantial, given the syndrome’s prevalence and mortality contribution, and given that cachexia involves chronic negative energy/protein balance[1, 2]. In that setting, carbohydrate-dominant formulas may persist because they are familiar, commonly available, and designed to be palatable and energy dense, even as the metabolic and oncologic implications of glycemic load remain incompletely addressed in outcome-driven trials within the provided dataset[1, 2, 8, 18].
Conclusions and recommendations
The dataset supports a coherent clinical concern: standard ONS and commercial enteral formulas commonly use carbohydrate as a major energy source, often via maltodextrin and other glucose-raising carbohydrates, and label examples show carbohydrate energy shares around ~45–47% of energy with substantial sugar content per serving volume[3–5]. Simultaneously, mechanistic frameworks link high glucose availability and hyperglycemia to enhanced glycolysis (Warburg biology), higher expression of glycolytic enzymes, and tumor-promoting signaling, while insulin/IGF-1 signaling is mechanistically connected to proliferation, survival, and mTOR-driven growth programs[2, 6, 8, 9]. Clinically, hyperglycemia is repeatedly associated with worse survival in specific oncology cohorts and settings, including advanced breast cancer and glioblastoma, and is supported by a meta-analysis across eight studies, though null findings exist in at least one metastatic colorectal cancer cohort[6–8, 24].
For cachexia, the central paradox is that the patients most likely to receive high-calorie formula support are also those characterized by insulin resistance, increased gluconeogenesis, inflammatory cytokine activation, and abnormal inflammatory biochemistry (including increased CRP)[1]. In such patients, “calorie delivery” and “metabolic compatibility” should be treated as dual clinical objectives, not competing philosophies, because energy deficit alone does not explain cachexia pathogenesis in about half of patients and metabolic alteration is central[2].
Based on evidence available here, the most actionable and evidence-supported recommendations are:
- Clinicians should actively monitor dysglycemia (e.g., mean glucose exposure) during nutrition support in cancer patients, given cohort associations between higher mean glucose and worse survival in some cancers and the demonstrated ability of formula macronutrient composition to affect glycemic dynamics[6, 7, 11, 12].
- Clinical nutrition researchers should prioritize randomized trials comparing metabolically tuned formulas (lower carbohydrate and/or altered carbohydrate type, higher fat including monounsaturated fat, with feasible fiber inclusion) against standard formulas, with endpoints that include glycemic control, inflammation markers (e.g., CRP, cytokines), body composition, functional outcomes, and survival where feasible[1, 2, 11, 12, 26].
- Formula innovation should be treated as a modifiable therapeutic exposure rather than a fixed commodity. The dataset demonstrates that substituting resistant maltodextrin can reduce insulin exposure by ~33% without changing macronutrient ratios, and that higher-fat/lower-carbohydrate enteral solutions can lower post-feeding glucose increases in hyperglycemic models[12, 22].
- In parallel, anti-inflammatory dietary patterns appear relevant after cancer diagnosis: pro-inflammatory diet indices are associated with higher mortality in colorectal cancer and in post-diagnosis cohorts, and a short randomized whole-food, plant-based intervention in metastatic breast cancer demonstrated significant reductions in inflammatory and tumor markers over 8 weeks[14–16]. While these findings do not directly replace the need for medical foods in malnourished patients, they reinforce that caloric adequacy should not be pursued without considering the metabolic and inflammatory context in which those calories are delivered[14, 16].
